Parametric Portfolio Associates’s BridgeBio Pharma BBIO Stock Holding History

Parametric Portfolio Associates’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.88M	Buy	185,533 +116,057	+167%	+$1.19M	﹤0.01%	2449
2021 Q4	$1.16M	Buy	69,476 +7,812	+13%	+$331K	﹤0.01%	2715
2021 Q3	$2.89M	Buy	61,664 +4,367	+8%	+$234K	﹤0.01%	2188
2021 Q2	$3.49M	Buy	57,297 +4,443	+8%	+$254K	﹤0.01%	2107
2021 Q1	$3.26M	Buy	52,854 +19,687	+59%	+$1.29M	﹤0.01%	2458
2020 Q4	$2.36M	Buy	33,167 +3,801	+13%	+$183K	﹤0.01%	2558
2020 Q3	$1.1M	Sell	29,366 -667	-2%	-$21K	﹤0.01%	2860
2020 Q2	$979K	Buy	30,033 +13,651	+83%	+$416K	﹤0.01%	2932
2020 Q1	$475K	Sell	16,382 -2,741	-14%	-$85K	﹤0.01%	3186
2019 Q4	$670K	Buy	19,123 +1,194	+7%	+$33.1K	﹤0.01%	3257
2019 Q3	$385K	Buy	+17,929	New	+$496K	﹤0.01%	3434

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AIG

American International Group New York $2.93M AUM 12.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Parametric Portfolio Associates's BBIO Position: Q1 2022 in Review

Parametric Portfolio Associates increased its BridgeBio Pharma (BBIO) stake by 167% in Q1 2022, buying an estimated $1.19M and bringing the position to 185,533 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2449.

Parametric Portfolio Associates first reported a position in BBIO in Q3 2019 and has held it in 11 quarters since. The position peaked at $3.49M in Q2 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

Parametric Portfolio Associates held 185,533 shares of BridgeBio Pharma worth $1.88M as of Q1 2022.
Parametric Portfolio Associates bought 116,057 BridgeBio Pharma shares in Q1 2022, an estimated $1.19M.
BridgeBio Pharma made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2449 holding.
Parametric Portfolio Associates first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 11 quarters since.
Parametric Portfolio Associates's BridgeBio Pharma position peaked at $3.49M in Q2 2021.
178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.